Benefits of GLP1 receptor agonists in high-risk individuals

GLP1 receptor agonists, such as somaglutide ozemic, have shown to reduce the risk of cardiovascular events in patients with type 2 diabetes and high risk for cardiovascular disease. Despite the slight increase in heart rate observed with these medications, the overall benefits are significant. The average pulse increase is only 2 beats per minute, which is not concerning. These medications have been used for 15 years and have consistently shown positive results in cardiovascular outcome trials. These findings provide reassurance regarding the safety and efficacy of GLP1 receptor agonists in high-risk individuals.